Target intelligence / Profile preview

Son of Sevenless homolog 1 - Kirsten rat sarcoma virus oncogene homolog protein-protein interaction interface (SOS1-KRAS PPI) (SOS1-KRAS PPI)

Target
SOS1-KRAS PPI
Molecular classification
Protein-protein interaction interface, Guanine nucleotide exchange factor (GEF)
01

Overview

The SOS1-KRAS protein-protein interaction interface is a critical regulatory node in the RAS/MAPK signaling pathway (UniProt Q07889, P01116). SOS1 (Son of Sevenless homolog 1) functions as a guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP on KRAS, thereby switching KRAS from an inactive to an active signaling state (PubMed: 32814534). This interaction is essential for the activation of both wild-type and various oncogenic mutant forms of KRAS, which drive approximately 25% of human cancers, including lung, colorectal, and pancreatic malignancies (PubMed: 31811050). Therapeutic targeting of this interface involves small molecules that bind to SOS1, disrupting its ability to engage KRAS and effectively "locking" KRAS in its inactive, GDP-bound form (PubMed: 31811050). This strategy is being explored as a monotherapy and in combination with direct KRAS inhibitors (e.g., G12C inhibitors) to prevent adaptive resistance and enhance clinical efficacy (ClinicalTrials.gov: NCT04111458).

Other names
SOS1-KRAS interaction interfaceSOS1-RAS interfaceSOS1-KRAS complexSOS1:KRAS interface
02

Mechanism of action

Inhibition of the SOS1-KRAS protein-protein interaction by small molecules that bind to the catalytic or allosteric sites of SOS1, preventing the nucleotide exchange of GDP for GTP and maintaining KRAS in its inactive state (PubMed: 31811050).

03

Biological functions

Signal transductionGTPase activationCell proliferationCell survival
04

Disease associations

Non-small cell lung cancerColorectal cancerPancreatic cancerNoonan syndrome
05

Safety considerations

Gastrointestinal toxicities (diarrhea, nausea, vomiting)Skin rashFatiguePotential off-target inhibition of other RAS-mediated physiological processes
06

Interacting drugs

BI-1701963

3 more in the full profile.

07

Biomarkers

KRAS G12C mutationKRAS G12D mutationKRAS G12V mutationPhosphorylated ERK (p-ERK) levelsDUSP6 mRNA levels

Beyond the preview

Go deeper on Son of Sevenless homolog 1 - Kirsten rat sarcoma virus oncogene homolog protein-protein interaction interface (SOS1-KRAS PPI) (SOS1-KRAS PPI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Son of Sevenless homolog 1 - Kirsten rat sarcoma virus oncogene homolog protein-protein interaction interface (SOS1-KRAS PPI) (SOS1-KRAS PPI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call